Big Changes At Bayer With Animal Health Exit And 12,000 Jobs Cut
Executive Summary
The German company is making some dramatic changes to its structure and in terms of pharma R&D, the focus will be very much on external alliances.
You may also be interested in...
Bayer's Job Cuts And Flat 2021 Sales Outlook Disappoint
Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.
Q4 Preview: How Will Bayer Survive Patent Cliff?
Ahead of the German major's fourth-quarter earnings call Feb. 27, analysts at Bernstein have been weighing up Bayer's chances of surviving the patent expiries on Xarelto and Eylea.
Bayer Still Confident Of Future Prospects Post-Xarelto
The German group has been talking up its pharmaceuticals division but analysts are not convinced it has addressed the elephant in the room that is the loss of patent protection for its blockbuster anticoagulant Xarelto in 2024.